Guess this is a good news/bad news situation. The info below is from Rick at LymeInfo. . .
Here is the abstract of Dr. Fallon's article published electronically ahead of the print version.
It took approx a year and a half for Dr. Fallon's paper to be reviewed for publication from the date it was submitted to the date it was accepted. And then, it took another three months before e-pub. Such scrutiny! Such intense peer-review!
IDSA gets their treatment guidelines accepted on the same day they are submitted! Were they even reviewed?
Oh the politics of peer-review! I guess it's more about the company you keep than the actual content of your research...
- Rick
- -
From the journal Neurology, the official journal of the American Academy of Neurology.
Published online before print October 10, 2007
(Neurology 2007, doi:10.1212/01.WNL.0000284604.61160.2d)
Received February 12, 2006 Accepted June 26, 2007
www.neurology.org/cgi/content/abstract/01.WNL.0000284604.61160.2dv1 or
tinyurl.com/yuq75c A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy
B. A. Fallon MD*, J. G. Keilp PhD, K. M. Corbera MD, E. Petkova PhD, C. B. Britton MD, E. Dwyer MD, I. Slavov PhD, J. Cheng MD, PhD, J. Dobkin MD, D. R. Nelson PhD, and H. A Sackeim PhD
From the Department of Psychiatry (B.A.F., J.G.K., K.M.C., E.P., I.S., J.C., H.A.S.), Department of Biostatistics (E.P.), Department of Neurology (C.B.B.), Department of Medicine (E.D., J.D.), and New York State Psychiatric Institute (B.A.F., J.G.K., K.M.C., E.P., I.S., J.C., H.A.S.), Columbia University, New York; and Department of Cell and Molecular Biology, University of Rhode Island, Kingston (D.R.N.).
* To whom correspondence should be addressed:
E-mail: baf1@columbia.edu Dr. Fallon
Background:
Optimal treatment remains uncertain for patients with cognitive impairment that persists or returns after standard IV antibiotic therapy for Lyme disease.
Methods:
Patients had well-documented Lyme disease, with at least 3 weeks of prior IV antibiotics, current positive IgG Western blot, and objective memory impairment. Healthy individuals served as controls for practice effects. Patients were randomly assigned to 10 weeks of double-masked treatment with IV ceftriaxone or IV placebo and then no antibiotic therapy. The primary outcome was neurocognitive performance at week
12—specifically, memory. Durability of benefit was evaluated at week
24. Group differences were estimated according to longitudinal mixed-effects models.
Results:
After screening 3368 patients and 305 volunteers, 37 patients and 20 healthy individuals enrolled. Enrolled patients had mild to moderate cognitive impairment and marked levels of fatigue, pain, and impaired physical functioning. Across six cognitive domains, a significant treatment-by-time interaction favored the antibiotic-treated group at week 12. The improvement was generalized (not specific to domain) and moderate in magnitude, but it was not sustained to week 24. On secondary outcome, patients with more severe fatigue, pain, and impaired physical functioning who received antibiotics were improved at week 12, and this was sustained to week 24 for pain and physical functioning. Adverse events from either the study medication or the PICC line were noted among 6 of 23 (26.1%) patients given IV ceftriaxone and among 1 of 14 (7.1%) patients given IV placebo; these resolved without permanent injury.
Conclusion:
IV ceftriaxone therapy results in short-term cognitive improvement for patients with posttreatment Lyme encephalopathy, but relapse in cognition occurs after the antibiotic is discontinued. Treatment strategies that result in sustained cognitive improvement are needed.
tinyurl.com/yuq75c